CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
November 2014—Sirion Biotech, in cooperation with University of Munich and University of Cologne, developed a line of viral vectors with specific promoters that are only active in a targeted set of cells to initiate the desired gene expression. Using this method, the gene of interest is being expressed only in the targeted tissue relevant to the desired therapy. The method is designed to improve the effectiveness of therapy and reduce the likelihood of side effects.
Read More »